Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis

Liver International

Volumn 26, Issue 1, 2006, Pages 39-45

  Abiru, Seigo ^a   Migita, Kiyoshi ^a   Maeda, Yumi ^a   Daikoku, Manabu ^a   Ito, Masahiro ^a   Ohata, Kazuyuki ^a   Nagaoka, Shinya ^a   Matsumoto, Takehiro ^a   Takii, Yasushi ^a   Kusumoto, Koichiro ^a   Nakamura, Minoru ^a   Komori, Atsumasa ^a   Yano, Koji ^a   Yatsuhashi, Hiroshi ^a   Eguchi, Katsumi ^b   Ishibashi, Hiromi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokines; Interleukin 6; Non alcoholic steatohepatitis; Tumor necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; RECEPTORS, CYTOKINE; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646014467     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01191.x     Document Type: Article

References (34)

1. Matteoni C A, Younossi Z M, Gramlich T, Boparai N, Liu Y C, McCullough A J. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
2. Neuschwander-Tetri B A, Caldwell S H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.
3. Day C P, James O F. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998; 114: 842-5.
4. Mehta K, Van Thiel D H, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants. Nutr Rev 2002; 60: 289-93.
5. Tilg H, Diehl A M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
6. Wigg A J, Roberts-Thomson I C, Dymock R B, McCarthy P J, Grose R H, Cummins A G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11.
7. Kugelmas M, Hill D B, Vivian B, Marsano L, McClain C J. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-9.
8. Chitturi S, Abeygunasekera S, Farell G C, Holmes-Walker J, Hui J M, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
9. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002; 35: 367-72.
10. Czaja M J. Liver injury in the setting of steatosis: Crosstalk between adipokine and cytokine. Hepatology 2004; 40: 19-22.
11. Hirano T. Molecular basis underlying functional pleiotropy of cytokines and growth factors. Biochem Biophys Res Commun 1999; 260: 303-8.
12. Bemelmans M H, Van Tits L J, Buurman W A. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996; 16: 1-11.
13. Brunt E M. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21: 3-16.
14. Brunt E M, Janney C G, Di Bisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
15. Valenti L, Fracanzani A L, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
16. Diehl A M. Cytokine regulation of liver injury and repair. Immunol Rev 2000; 174: 160-71.
17. Warzocha K, Bienvenu J, Coiffier B, Salles G. Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Eur Cytokine Netw 1995; 6: 83-96.
18. Naveau S, Abella A, Raynard B, Balian A, Giraud V, Montembault S, et al. Tumor necrosis factor soluble receptor p55 and lipid peroxidation in patients with acute alcoholic hepatitis. Am J Gastroenterol 2001; 96: 3361-7.
19. Yin M, Gabele E, Wheeler M D, et al. Alcohol-induced free radicals in mice: Direct toxicants or signaling molecules? Hepatology 2001; 34: 935-42.
20. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
21. Ramadori G, Christ B. Cytokines and the hepatic acute-phase response. Semin Liver Dis 1999; 19: 141-55.
22. Willner I R, Waters B, Patil S R, et al. Ninety patients with nonalcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-61.
23. Bugianesi E, Zannoni C, Vanni E, et al. Non-alcoholic fatty liver and insulin resistance: A cause-effect relationship? Dig Liver Dis 2004; 36: 165-73.
24. Guerre-Millo M. Adipose tissue and adipokines: For better or worse. Diabetes Metab 2004; 30: 13-9.
25. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
26. Senn J J, Klover P J, Nowak I A, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-9.
27. Kim H J, Higashimori T, Park S Y, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004; 53: 1060-7.
28. Kloverl P J, Zimmers T A, Koniaris L G, et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52: 2784-9.
29. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69.
30. Hirano T. Interleukin 6 and its receptor: Ten years later. Int Rev Immunol 1998; 16: 249-84.
31. Kallen K J. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002; 1592: 323-43.
32. Kishimoto T, Akira S, Taga T. IL-6 receptor and mechanism of signal transduction. Int J Immunopharmacol 1992; 14: 431-8.
33. Jones S A, Horiuchi S, Topley N, et al. The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. FASEB J 2001; 15: 43-58.
34. Jones S A, Rose-John S. The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 2002; 1592: 251-63.